These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3385720)

  • 81. Acute hepatitis after tetrahydroaminoacridine administration for Alzheimer's disease.
    Hammel P; Larrey D; Bernuau J; Kalafat M; Fréneaux E; Babany G; Degott C; Feldmann G; Pessayre D; Benhamou JP
    J Clin Gastroenterol; 1990 Jun; 12(3):329-31. PubMed ID: 2362104
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The effect of food on the bioavailability of velnacrine (HP 029) in healthy elderly men: a potential Alzheimer agent.
    Puri SK; Hsu RS; Ho I; Lassman HB
    J Clin Pharmacol; 1989 Oct; 29(10):956-60. PubMed ID: 2592587
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Heterogeneity of adverse hepatic reactions to tetrahydroaminoacridine.
    Ames DJ; Bhathal PS; Davies BM; Fraser JR; Gibson PR; Roberts S
    Aust N Z J Med; 1990 Apr; 20(2):193-5. PubMed ID: 2344330
    [TBL] [Abstract][Full Text] [Related]  

  • 84. New cyclopentaquinoline and 3,5-dichlorobenzoic acid hybrids with neuroprotection against oxidative stress for the treatment of Alzheimer's disease.
    Czarnecka K; Girek M; Kręcisz P; Skibiński R; Łątka K; Jończyk J; Bajda M; Szymczyk P; Galita G; Kabziński J; Majsterek I; Espargaró A; Sabate R; Szymański P
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2158822. PubMed ID: 36629422
    [TBL] [Abstract][Full Text] [Related]  

  • 85. New Tetrahydroacridine Hybrids with Dichlorobenzoic Acid Moiety Demonstrating Multifunctional Potential for the Treatment of Alzheimer's Disease.
    Czarnecka K; Girek M; Wójtowicz P; Kręcisz P; Skibiński R; Jończyk J; Łątka K; Bajda M; Walczak A; Galita G; Kabziński J; Majsterek I; Szymczyk P; Szymański P
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32466601
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.
    Goa KL; Fitton A
    CNS Drugs; 1994 Mar; 1(3):232-40. PubMed ID: 27520522
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Interaction of tacrine and velnacrine with neocortical synaptosomal membranes: relevance to Alzheimer's disease.
    Butterfield DA; Hensley K; Hall N; Umhauer S; Carney J
    Neurochem Res; 1993 Sep; 18(9):989-94. PubMed ID: 8232727
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Alzheimer's disease: fundamental and therapeutic aspects.
    Schorderet M
    Experientia; 1995 Feb; 51(2):99-105. PubMed ID: 7875258
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Quantitative whole-body autoradiographic determination of tacrine tissue distribution in rats following intravenous or oral dose.
    McNally W; Roth M; Young R; Bockbrader H; Chang T
    Pharm Res; 1989 Nov; 6(11):924-30. PubMed ID: 2594683
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Therapeutic effect of THA on hemicholinium-3-induced learning impairment is independent of serotonergic and noradrenergic systems.
    Hagan JJ; Jansen JH; Nefkens FE; de Boer T
    Psychopharmacology (Berl); 1990; 101(3):376-83. PubMed ID: 2362954
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Diagnostic and pharmacological approaches in Alzheimer's disease.
    Hermann C; Stern RG; Losonzcy MF; Jaff S; Davidson M
    Drugs Aging; 1991 Mar; 1(2):144-62. PubMed ID: 1794010
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Effects of tacrine, velnacrine (HP029), suronacrine (HP128), and 3,4-diaminopyridine on skeletal neuromuscular transmission in vitro.
    Braga MF; Harvey AL; Rowan EG
    Br J Pharmacol; 1991 Apr; 102(4):909-15. PubMed ID: 1649660
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I.
    Sarter M; Hagan J; Dudchenko P
    Psychopharmacology (Berl); 1992; 107(2-3):144-59. PubMed ID: 1615119
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Tacrine in Alzheimer's disease.
    Levy R
    Lancet; 1989 Aug; 2(8658):329. PubMed ID: 2569126
    [No Abstract]   [Full Text] [Related]  

  • 95. [Tetrahydroaminoacridine: a promising 'therapy' for Alzheimer's disease?].
    Drukarch B; Stoof JC
    Ned Tijdschr Geneeskd; 1988 Oct; 132(40):1833-5. PubMed ID: 3185771
    [No Abstract]   [Full Text] [Related]  

  • 96. Possible role of hydroxylated metabolites of tacrine in drug toxicity and therapy of Alzheimer's disease.
    Patocka J; Jun D; Kuca K
    Curr Drug Metab; 2008 May; 9(4):332-5. PubMed ID: 18473751
    [TBL] [Abstract][Full Text] [Related]  

  • 97. (+/-)-9-Amino-1,2,3,4-tetrahydroacridin-1-ol. A potential Alzheimer's disease therapeutic of low toxicity.
    Shutske GM; Pierrat FA; Cornfeldt ML; Szewczak MR; Huger FP; Bores GM; Haroutunian V; Davis KL
    J Med Chem; 1988 Jul; 31(7):1278-9. PubMed ID: 3385720
    [No Abstract]   [Full Text] [Related]  

  • 98. 9-Amino-1,2,3,4-tetrahydroacridin-1-ols: synthesis and evaluation as potential Alzheimer's disease therapeutics.
    Shutske GM; Pierrat FA; Kapples KJ; Cornfeldt ML; Szewczak MR; Huger FP; Bores GM; Haroutunian V; Davis KL
    J Med Chem; 1989 Aug; 32(8):1805-13. PubMed ID: 2754707
    [TBL] [Abstract][Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.